Authors
Latest:
Individualized Beta-Lactam Therapy and MonitoringElevated beta-lactam concentrations have been associated with neurotoxic adverse effects, including seizures and mental status changes.
Latest:
A Chance to Improve Hepatitis C Care for PWIDHere is a review of an opportunistic treatment approach to HCV infection in this patient population in a European study and some of the potential challenges in applying it in the United States.
Latest:
Those With HIV Shown to Have More Coronary PlaqueEven if HIV-positive individuals have a low-to-moderate risk for cardiovascular disease, they still experience more coronary plaque.
Latest:
10 Key Pillars to an Effective Ebola ResponseEVD outbreaks this year serve as a reminder of the virus’ severity and the importance of having a containment strategy in place.
Latest:
Intravenous Antimicrobials: Is It Time to Push?Intravenous (IV) push is an attractive option to administer antimicrobial therapy to patients in an efficient and effective manner in a variety of clinical settings. While many advantages to IV push administration exist, clinicians should be mindful of available literature regarding safety profiles, pharmacokinetic/pharmacodynamic characteristics, and clinical data for IV push antimicrobial administration prior to utilizing it in specific patient populations.
Latest:
Oral Therapeutic Options to Prevent Disease Progression From COVID-19 in an Ambulatory SettingAs the number of COVID-19 cases continues to rise, oral treatment options for at-home use are in demand to provide early intervention and reduce the progression to severe disease, hospitalization, and death.
Latest:
Navigating Long COVID and ME/CFS OverlapAlba Azola, MD discusses the challenges of diagnosing and managing Long COVID and its overlap with ME/CFS, emphasizing the need for individualized care and ongoing research.
Latest:
Daptomycin as Frontline Therapy for MRSA Bacteremia: Has the Time Come?Findings increasingly suggest the mortality risk may be reduced by initiating daptomycin within 3 days of infection.
Latest:
Combating Misinformation on AntimicrobialsInsights from Catherine Bertrand Ferrandis, DVM, on the role of One Health and interdisciplinary collaboration.
Latest:
Phase II Study Shows Efficacy of 6-Month Regimen of Lenacapavir, Teropavimab, and Zinlirvimab for HIVOnyema Ogbuagu, MBBCh, FACP, FIDSA discussed 96% virologic suppression with lenacapavir-based therapy, showing similar results to daily oral regimens.
Latest:
Challenges and Implications of the V Quinn TB Prevention TrialGregory Fox, PhD outlines the trial's challenges, the impact of combining results with the TB Champ trial, and the role of collaboration in strengthening research outcomes.
Latest:
Treating Persistent Methicillin-susceptible Staphylococcus aureus (MSSA) BacteremiaEmerging treatment options for patients with persistently positive blood cultures with Methicillin-Susceptible Staphylococcus aureus (MSSA).
Latest:
Pandemic Public Health Policy and Trust: Did We Lose the Latter Through the Former’s Actions?In the second installment of our interview with Robert Hopkins Jr, MD, the medical director of the National Foundation for Infectious Diseases (NFID), he discusses some of the takeaways in how public health messaging was lost on the public, which lead to mistrust, and thus leaving open the door for disinformation and misinformation.
Latest:
The Tripledemic as a Precursor to Stakeholder Alignment under the Quintuple AimInfectious disease outbreaks will continue to increase and trying to find strategies to ensure providers are cared for to prevent burnout and shortage staffing is essential if another pandemic arises.
Latest:
A Plea for New Guidance and Research: Low-Level Viremia in Persons Living With HIVCurrent guidelines and primary literature for managing persons living with HIV who have persistently low levels of HIV RNA are scarce. Considering the risks associated with this phenomenon, a call for further guidance and more robust studies are needed for these patients.
Latest:
Understanding the Nuances of the RSV Maternal Vaccine and Monoclonal Antibody for the Pediatric PopulationWith the approval of newer products, clinicians have tools to prevent the respiratory virus in the most vulnerable population. Helen Chu, MD, MPH, offers some insights on their efficacy and the nuances of the delivery of the 2 immunizations.
Latest:
The Next Generation of COVID-19 Vaccines and BoostersWill there be an answer to keep the continuously evolving virus at bay? Are seasonal combination vaccines the wave of the future?
Latest:
Revisiting Old Foes: Updates on HSVHerpes simplex viruses are chronic infections that underscore racial and ethnic disparities and are afflicting adolescents in increasing numbers.
Latest:
“Triple Therapy” Facing Triple ThreatClinicians provide an overview of intraamniotic infections and offer treatment strategies for these challenging infections.
Latest:
CDC Updates Pneumococcal Conjugate Vaccine RecommendationsThe federal agency recommends using either PCV13 or PCV15 as part of a 4-dose series for pediatric patients between the ages of 2-59 months.
Latest:
Antimicrobial Stewardship: How to Extend a Solid HandshakeIn the latest column from SIDP, handshake stewardship prioritizes face-to-face communication between frontline providers to enable feedback to assess the appropriateness of prescribed antimicrobials.
Latest:
Secnidazole Offers Hope as Option for Treating Trichomoniasis in WomenThis nitroimidazole antibiotic is shown to be efficacious for this condition.
Latest:
Antibiotic Stewardship in Outpatient CareAlthough there are challenges for clinical and infectious disease pharmacists when trying to apply this concept, here are some considerations and strategies to employ stewardship in this setting.
Latest:
Long-Acting Lipoglycopeptides for the Treatment of Severe InfectionsLong-acting lipoglycopeptides (LGPs) like dalbavancin, oritavancin, and telavancin were developed with extended half-lives, initially targeting acute bacterial skin and skin structure infections (ABSSSIs). However, recent studies have explored their potential in treating other infections, including infective endocarditis (IE), bone and joint infections (BJIs), and bloodstream infections (BSIs), offering an alternative to standard care and outpatient antimicrobial therapy.
Latest:
340B Drug Pricing Program: What Is It and Why Is It Important?The 340B program has had a great impact on access to HIV treatment and prevention services in the US.
Latest:
Mixed Fungal Brain AbscessClinicians review a patient case including diagnosis, treatment, and follow-up.
Latest:
MRNA COVID-19 Vaccines and Male FertilityAccording to a small study, the Moderna and Pfizer COVID-19 vaccines do not impact male fertility.
Latest:
Multidisciplinary Perspectives on HIV TreatmentA multidisciplinary panel concludes a discussion on best practices for managing patients with HIV in various healthcare settings and overcoming social health disparities.
